Department of Urology, The Chinese PLA 252 Hospital, 071000 Baoding, Hebei Province, PR China.
Eur J Surg Oncol. 2012 Apr;38(4):367-73. doi: 10.1016/j.ejso.2012.01.003. Epub 2012 Jan 20.
To avoid the misdiagnosis of prostate cancer (PCA), many patients receive repeated biopsies, despite receiving prior negative biopsies for PCA. Signal transduction and activators of transcription 3 (STAT3), a component of the JAK-STAT signaling pathway, can be activated by tyrosine phosphorylation as P-STAT3 and involved in the regulation of cellular growth, survival and oncogenesis. We aimed to assess the reliability of detecting PCA from the expression of P-STAT3 in prostate tissue previously designated as a negative biopsy.
Prostate tissues were obtained from the biopsies of 52 patients with localized PCA as well as from the biopsies of 80 patients free of PCA. Expression of P-STAT3 in these specimens was examined by immunohistochemical staining (IHC) and used to distinguish tissue with PCA from tissue designated as benign during a biopsy procedure.
P-STAT3 staining intensities in all samples (initial negative biopsies, cancer positive cores and other negative cores from the same-batch biopsies) of PCA patients was significantly higher than that of benign patients (F = 23.664, P < 0.001). Analysis of the receiver operating characteristics (ROC) curve showed that the area under curve (AUC) for P-STAT3 staining was 0.785. When positive immuno-labeling of P-STAT3 in samples from initial biopsies was used as a marker for PCA, it showed relatively high sensitivity (80.8%) and specificity (76.3%).
IHC of P-STAT3 could be utilized to detect PCA patients with initial negative biopsies. As a result, it can be a potential adjunctive tool for current PCA diagnostic programs. P-STAT3 can predict the onset of PCA up to 40 months earlier than currently used diagnostic approaches.
为了避免前列腺癌（PCA）的误诊，许多患者在接受先前 PCA 阴性活检后，仍会接受重复活检。信号转导和转录激活因子 3（STAT3）是 JAK-STAT 信号通路的一个组成部分，可通过酪氨酸磷酸化被激活为 P-STAT3，并参与细胞生长、存活和肿瘤发生的调节。我们旨在评估通过先前被标记为阴性活检的前列腺组织中 P-STAT3 的表达来检测 PCA 的可靠性。
从 52 例局部 PCA 患者的活检组织和 80 例无 PCA 患者的活检组织中获得前列腺组织。通过免疫组织化学染色（IHC）检测这些标本中 P-STAT3 的表达，并用于区分活检过程中被标记为良性的组织和具有 PCA 的组织。
所有 PCA 患者（初始阴性活检、癌症阳性核心和同一批次活检中的其他阴性核心）样本的 P-STAT3 染色强度均明显高于良性患者（F = 23.664，P < 0.001）。对受试者工作特征（ROC）曲线的分析表明，P-STAT3 染色的曲线下面积（AUC）为 0.785。当初始活检样本中 P-STAT3 的阳性免疫标记用作 PCA 的标志物时，其显示出较高的敏感性（80.8%）和特异性（76.3%）。
P-STAT3 的 IHC 可用于检测初始阴性活检的 PCA 患者。因此，它可以成为当前 PCA 诊断方案的潜在辅助工具。P-STAT3 可以比目前使用的诊断方法提前 40 个月预测 PCA 的发生。
